EVOKE PHARMA, INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 44 rows in 2019. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2019-06-17: Reporting owner Gonyer David A; Form 4; Security Stock Option (Right to Buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2019-06-17: Reporting owner Gonyer David A; Form 4; Security Stock Option (Right to Buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2019-06-17: Reporting owner Gonyer David A; Form 4; Security Stock Option (Right to Buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2019-06-17: Reporting owner Gonyer David A; Form 4; Security Stock Option (Right to Buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2019-06-17 | Gonyer David A Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | +85,000 0 owned after | $3.07 exercise price | 2019-06-19 | |
| 2019-06-17 | Gonyer David A Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | +70,687 0 owned after | $3.04 exercise price | 2019-06-19 | |
| 2019-06-17 | Gonyer David A Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | +60,000 0 owned after | $3.04 exercise price | 2019-06-19 | |
| 2019-06-17 | Gonyer David A Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | +225,000 0 owned after | $2.36 exercise price | 2019-06-19 | |
| 2019-06-17 | Gonyer David A Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | +225,000 0 owned after | $2.43 exercise price | 2019-06-19 | |
| 2019-06-17 | Gonyer David A Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | +225,000 0 owned after | $2.94 exercise price | 2019-06-19 | |
| 2019-06-17 | Gonyer David A Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −63,750 63,750 owned after | $0.62 exercise price | 2019-06-19 | |
| 2019-06-17 | Gonyer David A Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −53,015 53,015 owned after | $0.62 exercise price | 2019-06-19 | |
| 2019-06-17 | Gonyer David A Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −45,000 45,000 owned after | $0.62 exercise price | 2019-06-19 | |
| 2019-06-17 | Gonyer David A Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −168,750 168,750 owned after | $0.62 exercise price | 2019-06-19 | |
| 2019-06-17 | Gonyer David A Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −168,750 168,750 owned after | $0.62 exercise price | 2019-06-19 | |
| 2019-06-17 | Gonyer David A Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −168,750 168,750 owned after | $0.62 exercise price | 2019-06-19 | |
| 2019-06-17 | D'Onofrio Matthew J Officer (Exec VP, Chief Bus. Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | +65,000 0 owned after | $3.07 exercise price | 2019-06-19 | |
| 2019-06-17 | D'Onofrio Matthew J Officer (Exec VP, Chief Bus. Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | +70,687 0 owned after | $3.04 exercise price | 2019-06-19 | |
| 2019-06-17 | D'Onofrio Matthew J Officer (Exec VP, Chief Bus. Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | +52,500 0 owned after | $3.04 exercise price | 2019-06-19 | |
| 2019-06-17 | D'Onofrio Matthew J Officer (Exec VP, Chief Bus. Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | +150,000 0 owned after | $2.36 exercise price | 2019-06-19 | |
| 2019-06-17 | D'Onofrio Matthew J Officer (Exec VP, Chief Bus. Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | +150,000 0 owned after | $2.43 exercise price | 2019-06-19 | |
| 2019-06-17 | D'Onofrio Matthew J Officer (Exec VP, Chief Bus. Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | +150,000 0 owned after | $2.94 exercise price | 2019-06-19 | |
| 2019-06-17 | D'Onofrio Matthew J Officer (Exec VP, Chief Bus. Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −48,750 48,750 owned after | $0.62 exercise price | 2019-06-19 | |
| 2019-06-17 | D'Onofrio Matthew J Officer (Exec VP, Chief Bus. Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −53,015 53,015 owned after | $0.62 exercise price | 2019-06-19 | |
| 2019-06-17 | D'Onofrio Matthew J Officer (Exec VP, Chief Bus. Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −39,375 39,375 owned after | $0.62 exercise price | 2019-06-19 | |
| 2019-06-17 | D'Onofrio Matthew J Officer (Exec VP, Chief Bus. Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −112,500 112,500 owned after | $0.62 exercise price | 2019-06-19 | |
| 2019-06-17 | D'Onofrio Matthew J Officer (Exec VP, Chief Bus. Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −112,500 112,500 owned after | $0.62 exercise price | 2019-06-19 | |
| 2019-06-17 | D'Onofrio Matthew J Officer (Exec VP, Chief Bus. Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −112,500 112,500 owned after | $0.62 exercise price | 2019-06-19 | |
| 2019-06-17 | CARLSON MARILYN R. Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −50,000 0 owned after | $3.07 exercise price | 2019-06-19 | |
| 2019-06-17 | CARLSON MARILYN R. Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −75,000 0 owned after | $3.04 exercise price | 2019-06-19 | |
| 2019-06-17 | CARLSON MARILYN R. Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −33,750 0 owned after | $3.04 exercise price | 2019-06-19 | |
| 2019-06-17 | CARLSON MARILYN R. Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −100,000 0 owned after | $2.36 exercise price | 2019-06-19 | |
| 2019-06-17 | CARLSON MARILYN R. Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −125,000 0 owned after | $2.43 exercise price | 2019-06-19 | |
| 2019-06-17 | CARLSON MARILYN R. Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −125,000 0 owned after | $2.94 exercise price | 2019-06-19 | |
| 2019-06-17 | CARLSON MARILYN R. Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +37,500 37,500 owned after | $0.62 exercise price | 2019-06-19 | |
| 2019-06-17 | CARLSON MARILYN R. Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +56,250 56,250 owned after | $0.62 exercise price | 2019-06-19 | |
| 2019-06-17 | CARLSON MARILYN R. Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +25,312 25,312 owned after | $0.62 exercise price | 2019-06-19 | |
| 2019-06-17 | CARLSON MARILYN R. Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +75,000 75,000 owned after | $0.62 exercise price | 2019-06-19 | |
| 2019-06-17 | CARLSON MARILYN R. Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +93,750 93,750 owned after | $0.62 exercise price | 2019-06-19 | |
| 2019-06-17 | CARLSON MARILYN R. Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +93,750 93,750 owned after | $0.62 exercise price | 2019-06-19 | |
| 2019-05-02 | WIDDER KENNETH J Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +34,000 34,000 owned after | $0.72 exercise price | 2019-05-03 | |
| 2019-05-02 | RHOADS ANN D Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +36,500 36,500 owned after | $0.72 exercise price | 2019-05-03 | |
| 2019-05-02 | Hill Malcolm R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +32,500 32,500 owned after | $0.72 exercise price | 2019-05-03 | |
| 2019-05-02 | GARNER CAM L Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +37,500 37,500 owned after | $0.72 exercise price | 2019-05-03 | |
| 2019-05-02 | Brady Todd C Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +34,000 34,000 owned after | $0.72 exercise price | 2019-05-03 | |
| 2019-02-06 | CARLSON MARILYN R. Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +125,000 125,000 owned after | $2.94 exercise price | 2019-02-08 | |
| 2019-02-06 | D'Onofrio Matthew J Officer (Exec VP, Chief Bus. Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +150,000 150,000 owned after | $2.94 exercise price | 2019-02-08 | |
| 2019-02-06 | Gonyer David A Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +225,000 225,000 owned after | $2.94 exercise price | 2019-02-08 |